Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms	Hemic and Lymphatic Diseases, T-cell and NK-cell neoplasm, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome	Recruiting	Phase 2	2026-01-29		NCT04858256

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
CTI BioPharma	2
Hoosier Cancer Research Network	7
National Cancer Institute (NCI)	3015
National Institutes of Health (NIH)	667
University of Michigan Rogel Cancer Center	63

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
City of Hope	Duarte	United States	238
Duke Cancer Institute	Durham	United States	47
Moffitt Cancer Center	Tampa	United States	523
Ohio State University Comprehensive Cancer Center	Columbus	United States	2
University of Michigan Rogel Cancer Center	Ann Arbor	United States	186
University of Pittsburgh Medical Center	Pittsburgh	United States	63